Results 61 to 70 of about 135,031 (119)

Clinical features and outcomes of peripheral T-cell lymphoma, not otherwise specified: A single institution retrospective analysis of 30 cases. [PDF]

Oncol Lett
Ma MX, Zhang YL, Xing LN, Wang QY, Qiao S.   +4 more
europepmc   +1 more source

Primary Cutaneous Peripheral T-Cell Lymphoma With Follicular Helper T-Cell Phenotype. [PDF]

J Cutan Pathol
Planella-Fontanillas N, Molina-Alvarez A, Colomo-Saperas L, Rovira R, Gonzàlez-Farré M, Barranco-Sanz C, Calvo X, Nadal-Pellisé C, Gallardo F, Pujol RM.   +9 more
europepmc   +1 more source

Can baseline red blood cell distribution width predict outcomes in peripheral T-cell lymphoma patients? [PDF]

Ann Hematol
Lan Y, Zhao Y, Sun J, Zhou, Wang J, Zheng X, Shi Y, Meng H, Wei J, Yang C, Yu W, Jin J, Tong H, Xie W.   +13 more
europepmc   +1 more source

Peripheral T-cell lymphoma in adult-onset familial hemophagocytic lymphohistiocytosis type 2 and heterozygous <i>LRBA</i> mutation. [PDF]

Haematologica
Tembrink M, Haverkamp T, Reinhardt HC, Hanoun M.   +3 more
europepmc   +1 more source

Successful Treatment of Peripheral T-cell Lymphoma Not Otherwise Specified in Bilateral Subconjunctiva: A Case Report. [PDF]

Cureus
Ota H, Arihiro K, Mihara K, Chikama TI.
europepmc   +1 more source

Rare case report and literature review of peripheral T-cell lymphoma presenting as massive gastrointestinal hemorrhage: an unusual etiology demanding emergency surgical intervention. [PDF]

Front Oncol
Liu Z, Zhang L, Chen Q, He H, Xiong Y, Peng W, Liu Y, Li G, Zhan L.   +8 more
europepmc   +1 more source

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study. [PDF]

Blood Adv
Tournilhac O, Bouabdallah K, Lecolant S, Hacini M, Laribi K, Bailly S, Belmondo T, Maerevoet M, Ysebaert L, Guidez S, Le Gouill S, Bonnet C, André M, Dupuis J, Thieblemont C, Bachy E, Daguindau N, Morschhauser F, Tricot S, Moulin C, Banos A, Houot R, Chauchet A, Gyan E, Cartron G, Farhat H, Camus V, Drenou B, Zerazhi H, Sibon D, Nicolas-Virelizier E, Delette C, Snauwaert S, Bailly S, Delarue R, Carras S, Ledoux-Pilon A, Parrens MC, Griolet S, Gaulard P, Delfau-Larue MH, de Leval L, Damaj GL.   +42 more
europepmc   +1 more source

Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database. [PDF]

J Pharm Health Care Sci
Takatsu N, Matsumoto J, Oka Y, Sakai T, Iwata N, Higashionna T, Takeda T, Hamano H, Zamami Y.   +8 more
europepmc   +1 more source

Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma. [PDF]

Blood Adv
Khan N, Dahi PB, Khimani F, Shustov AR, Shadman M, Ruan J, Moskowitz AJ, Zelenetz AD, Noy A, Straus DJ, Drullinsky P, Hamilton A, Kumar A, Sauter CS, Shah GL, Matasar MJ, Drill E, Davey T, Hancock H, Ganesan N, Galasso N, van Beisen K, Giralt S, Horwitz SM.   +23 more
europepmc   +1 more source

Brentuximab vedotin as monotherapy or combination therapy for cutaneous peripheral T cell lymphoma - a retrospective study. [PDF]

J Dtsch Dermatol Ges
Glatzel C, Hansen-Abeck I, Booken N, Düll J, Goebeler M, Schummer P, Wobser M.   +6 more
europepmc   +1 more source